Cub Crafters Inc. Helps Recreational Travelers Take Flight with Classic Piper Cub-inspired Planes

 

• Commercial airlines have seen a resurgence of air travel demand this year following two years of COVID restrictions that kept most people close to home, but many airlines found themselves overwhelmed by the crush of travelers and capped ticket availability
• Yakima, Washington based CubCrafters Inc. designs, builds, and tests unique light aircraft for those who want to fly themselves
• The company’s array of aircraft are inspired by the classic Piper PA-18 Super Cub and include a variety of the company’s own Cub-derivative, newly manufactured designs
• The light and ultralight aircraft market is expected to grow by the end of the decade from annual revenues of $7.5 billion to $11.9 billion at a CAGR of 5.9 percent between 2022 and 2030

When the movie “Top Gun” debuted in 1986, scores of Americans felt inspired to take up flying as a recreational pursuit. With the unveiling of the explosively popular sequel this summer, enthusiasts are seeing a new wave of newcomers to airborne travel (https://ibn.fm/GAeyR).

The ability to crisscross the country in a personal plane is an attainable dream for Americans who love the adventure of seeing life from the air and have the discipline to do the necessary training and budgeting to get off the ground. 

And after two and a half years of pandemic-related restrictions, summer commercial air travel for recreation surged this year as a result of renewed demand for long-distance vacations. Delta, American, United, JetBlue Airways, Spirit Airlines and Alaska Airlines each capped ticket availability after initially biting off more they could chew this year and having to cancel or delay a large number of flights to accommodate staffing schedules (https://ibn.fm/DKDGa).

Yakima, Wash.-based Cub Crafters (stylized as CubCrafters) has spent decades appealing to those who want to fly themselves by designing, building, testing, and selling best-of-class backcountry airplanes modeled on the classic Piper PA-18 Super Cub light aircraft, and the company’s own Cub-derivative newly manufactured designs.  CubCrafters offers various different models of aircraft that fit under FAA Certified (Part 23), Light Sport Aircraft (“LSA”), and Experimental Amateur Built (E/A-B) classifications.

CubCrafters sells finished aircraft as well as aircraft kits for experimental plane enthusiasts who enjoy the hands-on, DIY emotion of assembling things themselves. 

The company focuses on five main product lines — the Carbon Cub SS LSA, Carbon Cub FX EAB, Carbon Cub EX kit, the FAA certified XCub, and the classic Top Cub. The company first certified the CC18 Top Cub in 2004 based on the classic Piper design. More than a decade later, in 2016, the completely modern CC19 XCub was FAA certified and introduced by the company with higher performance and stronger structure than similar aircraft, able to fly farther, faster, and carry more with a useful load is as high as 1,084 pounds.

The quality and nimble performance exhibited by the original Carbon Cub made it the best-selling LSA of all time in the United States, according to the company. The clean sheet design, computer-aided and using 21st century materials that are lightweight and extremely strong, has put more than 1,000 Carbon Cubs in the air.

Analysts at ResearchandMarkets.com are forecasting strong tailwinds for the light and ultralight aircraft manufacture market. They see the market’s current value as $7.5 billion with expectations for growth to $11.9 billion by the end of the decade, at a CAGR of 5.9 percent from 2022 to 2030 (https://ibn.fm/20rUy).

“Engaging our customers has been hugely important,” CubCrafters’ President and CEO Patrick Horgan stated two years ago when the company drew attention for introducing a Cub with a nose wheel design instead of the usual tailwheel (https://ibn.fm/6PsrC).

“We went into this process not entirely sure if the market wanted to accept a nosewheel-type personal adventure Cub,” Horgan stated at the time. “(But) we’ve had people wanting to place deposits for this aircraft from day one. Our customers have made it very clear that they want us to build this airplane.”

That same year, CubCrafters also recorded a landmark event when it shipped its first new European Aviation Safety Agency-certified CC19 XCub to Europe for a customer who wanted to use it as a working tool for business travel across England, Wales, Scotland and Ireland, “enabling very efficient access to often remote parts of the islands” (https://ibn.fm/U3Djx).

For more information, visit the company’s website at www.CubCrafters.com.

NOTE TO INVESTORS: The latest news and updates relating to Cub Crafters Inc. are available in the company’s newsroom at https://ibn.fm/CUB

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate in Upcoming Canaccord Genuity Growth Conference

 Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting at the 42nd annual Canaccord Genuity Growth Conference; the four-day event is scheduled for Aug. 8–11, 2022, in Boston. During the conference, Cybin CEO Doug Drysdale will present a fireside chat. Drysdale’s presentation is slated for Thursday, Aug. 11, 2022, at 3:30 p.m. ET. Interested individuals are invited to watch a live webcast of the event or an archived version of the event, available on the company’s investor relations page following the live presentation.

To view the live presentation, visit https://ibn.fm/ghBjR

To view the full press release, visit https://ibn.fm/kOXQn

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

 

• Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearance
• Enrollment for Phase 1/2a trial has already started
• Upcoming trial is first time a psilocybin analog will be evaluated for MDD treatment
• Studies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin

In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/QfXhX) to proceed with its planned phase 1/2a first in-human clinical trial and has started enrollment (https://ibn.fm/HxkKp). The study is designed to evaluate Cybin’s proprietary deuterated psilocybin analog, CYB003. The approval came in the form of a “may proceed” letter and investigational new drug (“IND”) application clearance. 

“We are extremely pleased to advance CYB003 into clinical development so quickly,” said Cybin CEO Doug Drysdale. “Our team has worked diligently to achieve this major regulatory milestone, and we look forward to collaborating with Clinilabs, our drug-development partner, to accelerate this program. This phase 1/2a trial represents the first time that a psilocybin analog will be evaluated for the treatment of MDD and is the key next step toward our ultimate goal of providing a new and effective treatment for people suffering with mental health conditions.

“Successful patient recruitment and a proper clinical environment are integral components of this trial,” Drysdale also noted. “As a global leader in drug development services, Clinilabs is a perfect partner, and we are thankful for their support and guidance.” According to the company, this is the industry’s first-ever novel psilocybin analog to enter clinical development. 

Participants in the randomized, double-blind, placebo-controlled study will receive two administrations: placebo/active and active/active. In addition, a response/remission will be assessed after the first dose at week 3 and after the second dose at week 6. The announcement noted that study subjects currently being treated with selective serotonin reuptake inhibitors can remain on their antidepressant medication.

Specifically, the phase 1/2a study is designed to evaluate rapid onset of antidepressant effect on the day of dosing, as well as the benefit of CYB003 when administered at up to two 12mg doses. An optional open-label follow-up study will assess the durability of treatment effect out to 12 weeks. The study will use the Montgomery-Asberg Depression Rating Scale.

Cybin plans to provide an interim pharmacokinetic (“PK”) and safety data readout in quarter four of this year. The company anticipates that data from the studies will provide key PK and safety data to help the company identify future plans for its proprietary substance.

“Multiple academic studies have shown that psychedelic-based treatments, like psilocybin, may have the potential to revolutionize mental healthcare, but few companies have addressed the well-known limitations and side effects of oral psilocybin,” said Drysdale. “We believe CYB003 has the potential to offer people in need a more tolerable and potentially more effective treatment option. We look forward to advancing this important compound through clinical development.”

A deuterated analog of psilocybin, CYB003 is designed to effectively address the challenges and limitations of oral psilocybin. Based on preclinical data, CYB003 achieved less variability in plasma levels, faster onset of action and shorter duration of effect. “We believe CYB003 has the potential to reduce time and resource burden on patients, providers and payers, and possibly improve scalability and accessibility​ of treatment,” the company stated. 

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Increases to 19 Worldwide Lightning Network Nodes as FED Working Paper Supports Bitcoin Scalability Through the Network

 

• LQwD is leveraging the Lightning Network for BTC scalability with 19 nodes active and the goal of creating Lightning Network node access in 24 countries by the end of this financial quarter
• LQwD nodes include US-West, Ireland, India, Germany, Brazil, Hong Kong, Singapore, Sweden, South Korea, South Africa, Bahrain, Indonesia, Italy, Australia, Japan-Osaka, France, Canada, England, and Japan
• The cryptocurrency market was valued at US $1.6 billion in 2021 and is expected to reach $2.2 billion by 2026, growing at a CAGR of 7.1%

The Federal Reserve Bank of Cleveland Working Paper Series released Working Paper 22-19 in June 2022 entitled “The Lightning Network: Turning Bitcoin into Money.” The FED conjectures early on that the Lightning Network (“LN”) has reduced Bitcoin blockchain congestion and resulted in lower mining fees. Since its introduction in 2009, Bitcoin has grown in value but still has capacity constraints regarding payment processing capability. The average blockchain transaction only allows seven transactions per second, which pales in comparison with centralized payment infrastructures like Visa or Mastercard (https://ibn.fm/y36ZX).

The introduction of the Lightning Network has reduced the amount of time it takes for payment processing to provide almost instant results. The overall consensus is that the Network can help Bitcoin achieve greater scalability as a payments system and states, “According to our results, if the LN had existed in 2017, congestion could have been 93 percent lower,” the paper says.

The Lightning Network was designed as a viable solution to massively scale bitcoin on a global level, dramatically increasing the number of transactions, lowering the fees associated with transactions, and creating instant settlement times for microtransactions. The LN is a layer 2 payment protocol and eases the scalability of using bitcoin transactions to make payments quickly, easily, and securely using Bitcoin or Litecoin for transactions.

One company focused on increasing the scalability of Bitcoin and transactions using the LN by creating enterprise-grade infrastructure is LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF). In November 2021, LQwD released its platform-as-a-service (“PaaS”) offering, https://lqwd.tech/, which serves as a platform for node hosting and managing channels on the LN, and acts as a Liquidity Service Provider (“LSP”) for merchants. LQwD’s nodes are distributed globally to allow for maximum scalability and growth.

Through LQwD’s PaaS, users have access to a network of LN nodes that allow for faster transactions, lower fees, and higher levels of security. As a publicly traded company, LQwD is leveraging its position with the public to enhance trust in its products and services, easily access capital through the market, leverage its stock as currency for acquisitions, and attract/retain top industry talent to further provide scalable solutions that enhance the adoption of Bitcoin. 

LQwD’s first node (US-West) launched in November 2021 and is now the company’s oldest operational node with a capacity of over 6 BTC and 117 open channels. LQwD currently has 19 active nodes worldwide on the LN, including US-West, Ireland, India, Germany, Brazil, Hong Kong, Singapore, Sweden, South Korea, South Africa, Bahrain, Indonesia, Italy, Australia, Japan-Osaka, France, Canada, England, and Japan. The two newest nodes are located in Australia and Japan-Osaka. The company’s goal is to be operational with nodes spanning 24 countries worldwide by the end of the current financial quarter.

In 2021, the cryptocurrency market size was valued at US $1.6 billion, and it is expected to reach US $2.2 billion by 2026, growing at a CAGR of 7.1% over the forecast period. The market’s growth can be attributed to the economic conditions and a rise in demand for cryptocurrency across various applications. The launch of various hardware and software companies has contributed to this industry’s growth. LQwD is leveraging its position in this market to bring larger scalability to the Lightning Network and Bitcoin potential (https://ibn.fm/8u8YY).

For more information, visit the company’s website at www.LQwDFinTech.com.

NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Pro Athletes Provide Specialized Advocacy for Odyssey Health, Inc.’s (ODYY) Solution for Concussion-related Brain Injuries

 

• CDC estimates put the incidence of athlete concussion incidents at 5 to 10 percent of players
• Currently, there is no FDA-approved medicinal treatment for helping people with concussion injuries
• Odyssey Health Inc. is a company developing a drug-device combination to treat concussion patients in the first minutes after injury
• Retired pro soccer and football athletes Abby Wambach, Kurt Warner, and Brett Favre, have formed a Sports Advisory Board for Odyssey Health to help guide and promote public information regarding Odyssey’s treatment developments
• Wambach recently appeared on the Stock2Me podcast to discuss her interest in concussion research and her role on Odyssey’s sports board

The Center for Disease Control estimates that 5 to 10 percent of athletes will experience a concussion in any given sports season, marking the brain injury events as very common among athletes. 

Soccer and football stand out as that may exact a heavy toll in traumatic brain injuries (“TBIs”) because of the way head and neck impacts form a part of the games. 

The University of Michigan’s Health department cites statistics on the web page for its multidisciplinary NeuroSport program showing about 3.8 million concussions occur each year in the United States from sports-related injuries (https://ibn.fm/ywaND).

Retired pro soccer forward Abby Wambach and retired pro football quarterbacks Kurt Warner and Brett Favre have expressed hopes that medical science will yet be able to gain a better understanding of TBIs and how to treat them, particularly in regard to sports athletes. 

The trio have expressed a willingness to let forensic researchers learn from their donated cadaver brains to advance medical science, and they have formed a Sports Advisory Board for Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY), a company that is preparing for human trials of a drug product-device combination it believes will ultimately help concussion-injured individuals to quickly heal and recover. 

Currently, there is no medication approved by the U.S. Food and Drug Administration (“FDA”) for treating concussion injuries specifically, but Odyssey’s PRV-002 solution has shown promise and safe performance in animal testing. The human trial is enrolling volunteers to further establish the safety of Odyssey Health’s technology and is expected to then advance to a Phase II/III trial setup to show that PRV-002 technology is an effective option for concussed patients.

Wambach is an advocate for studying the differences between men and women in TBI vulnerability, degree of injury and measure of recovery since concussion-related attention generally focuses on men’s health (https://ibn.fm/yi3NW).

“In my retirement … I’ve had a lot of time to kind of reflect on the time that I played. I played soccer for 30 years and one of the biggest concerns that I have going into the rest of my life is my brain health,” Wambach told Stock2Me podcast host Stuart Smith in a July 13 interview (https://ibn.fm/PrSID).

“Of course, a lot of us really only think about concussions and CTE (chronic traumatic encephalopathy) as it relates to NFL football but the reality is brain trauma happens in every sport,” Wambach said. “And there’s just such little research done, not only on concussions themselves …, but also when you break it down into the genders of women and men, so many less dollars get siphoned over into the women’s side.”

Smith noted reports that show female athletes tend to be at much greater risk of traumatic brain injury events than male athletes and that they take longer to recover from them. 

“It’s not just about how much the women are getting paid, it’s how these woman are getting treated off the field with travel arrangements, etc.,” Wambach said. “That has actually nothing to do with research in the medical fields on women’s bodies for things like concussions, for things like CTE. That’s why my role on this board is, I think, so important. … Not just (for) the sports community, because we’re talking about the military community as well; we’re talking about older folks taking a fall. Any person who is dealing with any kind of head trauma will greatly benefit from research, from the production of treatments like this medicine that Odyssey is behind.”

For more information, visit the company’s website at www.OdysseyHealthInc.com.

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY 

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php